Pharmaceutical Business review

Skystar Q1 revenues up 46%

Skystar has reported a net income of $1.93m, or $0.27 per diluted share, compared to net income of $1.1m or $0.15 per diluted share, for the same period last year.

The company’s income from operations were $1.64m, as compared to $1.74m for the same period prior year.

Skystar’s gross profit was $3.6m, compared to $2.58m for the same period prior year.

Skystar chairman and CEO Weibing Lu said the goals of Skystar’s business plan and capital markets activity has been to develop and grow these initiatives.